Co-Diagnostics Analyzes Flu Virus Detection Technology with High Sensitivity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: PRnewswire
- Technology Stability: Co-Diagnostics performed an analysis of its Logix Smart ABC test's Co-Primers® against 3,900 influenza sequences, confirming comparable reactivity to the H3N2 subclade K, which underscores the stability and reliability of its technology since its initial development over five years ago.
- Market Demand: With this year's flu vaccine mismatched against subclade K, Co-Diagnostics has received inquiries from customers regarding the performance of the Logix Smart ABC test, indicating a sustained demand for high-quality PCR testing solutions in the market.
- Clinical Testing Initiation: In November 2025, the company initiated clinical performance testing for the Co-Dx PCR Flu A/B, COVID-19, RSV multiplex test, aimed at supporting a 510(k) submission to the FDA, thereby expanding its product line.
- Regulatory Compliance: Although the Logix Smart ABC test has received CE marking, it remains subject to FDA review processes, ensuring compliance and safety for market availability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
